Bioventus announced it has received FDA approval for Durolane, a single-injection hyaluronic acid product for joint lubrication in the treatment of pain associated with knee osteoarthritis.
According to a company press release, Bioventus currently markets and sells Durolane in more than 25 countries, including Canada, Mexico, Australia and throughout much of Europe, with plans to launch Durolane on the U.S. market in early 2018. The release reported that Durolane will comprise part of the company’s osteoarthritis (OA) portfolio along with the three-injection hyaluronic acid Gelsyn-3 and the five-injection hyaluronic acid Supartz FX.
“More than 20 million Americans are afflicted with knee osteoarthritis and there is no cure, but the associated pain can be managed,” Tony Bihl, CEO of Bioventus, said in the release. “Durolane has been a proven knee OA pain reliever for more than 15 years, improving the lives of more than one million people worldwide. It will join our current offerings to provide even more efficacious treatment options for U.S. patients, physicians and payers.”